FDA Advisors Reject New Obesity Pill

Published July 17, 2010

FDA Advisors Reject New Obesity Pill
A Food and Drug Administration (FDA) panel has rejected an experimental anti-obesity medication produced by Vivus, Inc. due to the potential safety risks, according to various media reports Friday.According to Matthew Perrone of the Associated Press, the FDA advisors "voted 10-6 against Vivus’s Qnexa, citing uncertainty about the potential risks that could come with long-term use of the …
Read more on redOrbit

FDA Panel Rejects Highly Anticipated Diet Pill
ATLANTA — A panel of federal health experts dealt a surprising setback Thursday to an anti-obesity pill from Vivus Inc., saying the drug’s side effects outweigh its ability to help patients lose weight.
Read more on First Coast News

FDA panel rejects weight loss pill
A panel of federal health experts dealt a surprising setback to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug’s side effects outweigh its ability to help patients lose weight.
Read more on The Clarion-Ledger